• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Inflection Point Acquisition Corp. V filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    12/22/25 5:00:57 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IPEX alert in real time by email
    false 0002028355 00-0000000 0002028355 2025-12-22 2025-12-22 0002028355 IPEX:UnitsEachConsistingOfOneClassOrdinaryShareAndOneRightMember 2025-12-22 2025-12-22 0002028355 IPEX:ClassOrdinarySharesParValue0.0001PerShareMember 2025-12-22 2025-12-22 0002028355 IPEX:RightsEachRightEntitlingHolderToReceiveOnefifth15OfOneClassOrdinaryShareUponCompletionOfCompanysInitialBusinessCombinationMember 2025-12-22 2025-12-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(D)
    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): December 22, 2025

     

    INFLECTION POINT ACQUISITION CORP. V

    (Exact name of registrant as specified in its charter)

     

    Cayman Islands   001-42518   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    167 Madison Ave, Suite 205 #1017
    New York, NY 10016

    (Address of principal executive offices, including zip code)

     

    212-476-6908
    (Registrant’s telephone number, including area code)

     

    Not Applicable
    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one Class A ordinary share and one right   IPEXU   The Nasdaq Stock Market LLC
    Class A ordinary shares, par value $0.0001 per share   IPEX   The Nasdaq Stock Market LLC
    Rights, each right entitling the holder to receive one-fifth (1/5) of one Class A ordinary share upon the completion of the Company’s initial business combination   IPEXR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    As previously disclosed, on October 13, 2025, Inflection Point Acquisition Corp. V (formerly known as Maywood Acquisition Corp.), a Cayman Islands exempted company (“SPAC”), GOWell Technology Limited, a Cayman Islands exempted company (the “Company”), GOWell Energy Technology, a Cayman Islands exempted company, and IPCV Merger Sub Limited, a Cayman Islands exempted company, entered into a Business Combination Agreement (the “Business Combination Agreement”). Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such term in the Business Combination Agreement, a copy of which was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by SPAC with the Securities and Exchange Commission (the “SEC”) on October 13, 2025.

     

    On December 22, 2025, SPAC and the Company entered into that certain Amendment to the Business Combination Agreement (the “Amendment”) in order to clarify the number of PubCo Series A Investor Warrants to be issued upon conversion of the Company Warrants at the Second Merger Effective Time.

     

    The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 2.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Additional Information and Where to Find It

     

    In connection with the proposed business combination between SPAC and the Company (the “Proposed Business Combination”), SPAC and the Company intend to prepare and file with the SEC a registration statement containing a preliminary proxy statement of SPAC and a preliminary prospectus with respect to the securities to be offered in the Proposed Business Combination. After the registration statement is declared effective, the SPAC will mail a definitive proxy statement/prospectus relating to the Proposed Business Combination to its shareholders as of a record date to be established for voting on the Business Combination Agreement, as amended by the Amendment, and the Proposed Business Combination. Investors, shareholders and other interested persons are urged to read these documents and any amendments thereto, as well as any other relevant documents filed with the SEC when they become available because they will contain important information about the SPAC, the Company and the Proposed Business Combination. Investors and shareholders will also be able to obtain free copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, once available, without charge, at the SEC’s website located at www.sec.gov, or by directing a request to Inflection Point Acquisition Corp. V, 167 Madison Avenue Suite 205 #1017, New York, NY 10016.

     

    Participants in the Solicitation

     

    The SPAC, the Company, and their directors and executive officers and other persons may be deemed to be participants in the solicitations of proxies from the SPAC’s shareholders in respect of the Proposed Business Combination and the other matters set forth in the registration statement. Information regarding the SPAC’s directors and executive officers is available in the SPAC’s Current Report on Form 8-K, which was filed with the SEC on September 12, 2025 and is available free of charge at the SEC’s website located at www.sec.gov, or by directing a request to Inflection Point Acquisition Corp. V, 167 Madison Avenue Suite 205 #1017, New York, NY 10016. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests by security holdings or otherwise, will be contained in the proxy statement/prospectus relating to the Proposed Business Combination when it becomes available.

     

    No Offer or Solicitation

     

    This Report and the exhibits hereto are for informational purposes only and are neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the Proposed Business Combination or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit   Description
    2.1   Amendment to Business Combination Agreement, dated as of December 22, 2025, by and between Inflection Point Acquisition Corp. V and GOWell Technology Limited.
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: December 22, 2025

     

      INFLECTION POINT ACQUISITION CORP. V
         
      By: /s/ Michael Blitzer
        Name: Michael Blitzer
        Title: Chief Executive Officer

     

    2

     

    Get the next $IPEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IPEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IPEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GOWell to Host Investor & Analyst Webinar on April 14, 2026

    SINGAPORE and NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- GOWell Technology Limited ("GOWell" or the "Company"), a global one-stop-shop for innovative well logging solutions in the energy sector, will host an Investor & Analyst Webinar on Tuesday, April 14, 2026 at 10:00 a.m. ET. The webinar will include a formal presentation and Q&A session with management. The Company previously announced that it had entered into a Business Combination Agreement with Inflection Point Acquisition Corp. V (NASDAQ:IPEX) ("IPEX"), on October 14, 2025. To register for this webinar, please use the registration link found here. Additionally, for those unable to listen to the live webcast, a recording will be

    3/31/26 6:00:00 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GOWell Technology Limited and Inflection Point Acquisition Corp. V Announce Public Filing of Registration Statement on Form F-4 in Connection with Proposed Business Combination

    SINGAPORE and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- GOWell Technology Limited ("GOWell" or the "Company"), a global one-stop-shop for innovative well logging solutions in the energy sector, and Inflection Point Acquisition Corp. V (NASDAQ:IPEX) ("Inflection Point"), a special purpose acquisition company, have announced the public filing of their joint registration statement on Form F-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") related to their previously announced business combination (the "Business Combination"). The Registration Statement contains a preliminary proxy statement/prospectus of Inflection Point that discloses importan

    3/25/26 6:03:49 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GOWell Technology Participates in Advanced Well Integrity Benchmarking Program Coordinated by an Independent Net Zero Organization

    SINGAPORE and NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- GOWell Technology Limited ("GOWell" or the "Company"), a global one-stop-shop for innovative well logging solutions in the energy sector, today announced its participation in a collaborative effort to evaluate next generation well integrity technologies. The evaluation was performed as part of an industry benchmarking program led by an independent Net Zero organization at the NORCE testing facility in Stavanger, Norway. This initiative assessed cutting-edge methods designed to address the industry's most urgent operational and sustainability challenges in well integrity evaluation. As global decommissioning activities accelerate, o

    12/18/25 8:30:00 AM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Trabuco Carolyn

    3 - Inflection Point Acquisition Corp. V (0002028355) (Issuer)

    1/20/26 5:01:12 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Blitzer Michael

    4 - Inflection Point Acquisition Corp. V (0002028355) (Issuer)

    1/5/26 9:41:33 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPEX
    SEC Filings

    View All

    SEC Form 425 filed by Inflection Point Acquisition Corp. V

    425 - Inflection Point Acquisition Corp. V (0002028355) (Subject)

    4/14/26 9:05:21 AM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inflection Point Acquisition Corp. V filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Inflection Point Acquisition Corp. V (0002028355) (Filer)

    4/14/26 9:00:26 AM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Inflection Point Acquisition Corp. V

    425 - Inflection Point Acquisition Corp. V (0002028355) (Subject)

    4/3/26 4:21:11 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care